# R-3750 in Patients With Mild to Moderate Ulcerative Colitis

> **NCT05666960** · PHASE1 · RECRUITING · sponsor: **Rise Therapeutics LLC** · enrollment: 36 (estimated)

## Conditions studied

- Ulcerative Colitis Chronic Mild
- Ulcerative Colitis Chronic Moderate
- Ulcerative Colitis Chronic
- Ulcerative Colitis

## Interventions

- **DRUG:** R-3750

## Key facts

- **NCT ID:** NCT05666960
- **Lead sponsor:** Rise Therapeutics LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-27
- **Primary completion:** 2026-07
- **Final completion:** 2026-10
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-01-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05666960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05666960, "R-3750 in Patients With Mild to Moderate Ulcerative Colitis". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05666960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*